INNODIA HARVEST

Translational approaches to disease modifying therapy of type 1 diabetes - HARVESTing the fruits of INNODIA

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 19
Grant agreement number
945268

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
5 999 055
EFPIA in kind
2 758 000
Associated Partners
3 685 389
Total Cost
12 442 444

Summary

IMI’s INNODIA project has added significantly to our understanding of type 1 diabetes (T1D). The aim of INNODIA HARVEST is to build on INNODIA’s results by carrying out additional activities that will further pave the way for new treatments to treat or even prevent T1D.

INNODIA HARVEST plans to consolidate the INNODIA clinical network and use it to run two clinical trials of drugs designed to stop T1D. One trial is driven by academia and focuses on the pancreatic beta cells, which are responsible for producing the hormone insulin. The other trial is industry driven and focuses on the role of the immune system (as the immune system attacks the beta cells in T1D).

Elsewhere, INNODIA HARVEST will continue INNODIA’s hunt for new biomarkers that could be used to track the progress of the disease, and implement new drug discovery pipelines for novel treatments for T1D

As in INNODIA, people with T1D and their families will be at the heart of the project to ensure the work meets their needs.

Participants Show participants on map

EFPIA companies
  • Eli Lilly and Company Limited, Basingstoke, United Kingdom
  • Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom
  • Imcyse SA, Sart Tilman, Belgium
  • Novartis Pharma AG, Basel, Switzerland
  • Novo Nordisk A/S, Bagsvaerd, Denmark
  • Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany
Universities, research organisations, public bodies, non-profit groups
  • Academisch Ziekenhuis Leiden, Leiden, Netherlands
  • Cardiff University, Cardiff, United Kingdom
  • Centre Hospitalier De Luxembourg, Luxembourg, Luxembourg
  • Hannoversche Kinderheilanstalt, Hannover, Germany
  • Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GMBH, Neuherberg, Germany
  • Institut National De La Sante Et De La Recherche Medicale, Paris, France
  • Katholieke Universiteit Leuven, Leuven, Belgium
  • King'S College London, London, United Kingdom
  • Kobenhavns Universitet, Copenhagen, Denmark
  • Lunds Universitet, Lund, Sweden
  • Medizinische Universitat Graz, Graz, Austria
  • Oslo Universitetssykehus Hf, Oslo, Norway
  • Ospedale Pediatrico Bambino Gesu, Rome, Italy
  • Oulun Yliopisto, Oulu, Finland
  • Region Hovedstaden, Hilleroed, Denmark
  • Slaski Uniwersytet Medyczny W Katowicach, Katowice, Poland
  • Stichting Katholieke Universiteit, Nijmegen, Netherlands
  • Technische Universitaet Dresden, Dresden, Germany
  • The University Of Exeter, Exeter, United Kingdom
  • Universita Degli Studi Di Siena, Siena, Italy
  • Universita Degli Studi Gabriele D'Annunzio Di Chieti-Pescara, Chieti, Italy
  • Universita Di Pisa, Pisa, Italy
  • Universita Vita-Salute San Raffaele, Milano, Italy
  • Universitaet Ulm, Ulm, Germany
  • Universite De Lausanne, Lausanne, Switzerland
  • University of Cambridge, Cambridge, United Kingdom
  • University of Helsinki, University of Helsinki, Helsinki, Finland
  • University of Oxford, Oxford, United Kingdom
  • University of Turku, Turku, Finland
  • Université Libre de Bruxelles, Bruxelles, Belgium
  • Univerza V Ljubljani, Ljubljana, Slovenia
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Univercell Biosolutions SAS, Toulouse, France
Associated partners
  • Jdrf International, New York, United States
  • The Leona M. And Harry B. Helmsley Charitable Trust, New York, United States
Project coordinator
Chantal Mathieu
Katholieke Universiteit Leuven